Malignant glioma: Should chemotherapy be overthrown by experimental treatments?

Annals of Oncology

Volumn 9, Issue 6, 1998, Pages 589-600

  Hosli P ^a   Sappino, A P ^a   De Tribolet, N ^a   Dietrich, P Y ^a,b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b University Hospital   (Switzerland)

Author keywords

Brain neoplasms; Chemotherapy; Gene therapy; Gtioma; Immunotherapy; Review literature

Indexed keywords

ANGIOSTAT; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IFOSFAMIDE; LOMUSTINE; METALLOPROTEINASE INHIBITOR; METHOTREXATE; MITOLACTOL; PACLITAXEL; PREDNISONE; PROCARBAZINE; TEMOZOLOMIDE; THIOTEPA; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TIOGUANINE; VINCRISTINE;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; GENE THERAPY; GLIOBLASTOMA; GROWTH INHIBITION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS; GENE THERAPY; GLIOMA; HUMANS; IMMUNOTHERAPY; PROGNOSIS;

EID: 0031852664     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008267312782     Document Type: Review

References (106)

1. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the brain tumor cooperative group. J Clin Oncol 1988; 6: 338-43.
2. Levin VA, Gutin PH, Leibel S, Cancer, Principles and Practice of Oncology. In De Vita VT Jr. Hellman S. Rosenberg SA (eds): Neoplasms of the Central Nervous System. Philadelphia: JB Lippincot 1993; 1679-737.
3. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30: 907-11.
4. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radial Oncol Biol Phys 1979; 5: 1725-31.
5. Walker MD, Green SB., Byar DP. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323-9.
6. Lesser GJ, Grossman S. The chemotherapy of high-grade astrocytomas. Semin Oncol 1994; 21: 220-35.
7. Petersdorf SH, Berger MS. Concepts in Neurosurgery: The molecular basis of neurosurgical disease. In Raffel C. Harsh IV GR (eds): Molecular Basis of Chemotherapy for Brain Tumors. Baltimore: Williams and Wilkins 1996; Chapter 12 (Vol 8): 198-210.
8. Janzer RC, Raff MC. Astrocytes induce blood brain barrier properties in endothelial cells. Nature 1987; 325: 253-7.
9. Mak M, Fung L. Strasser JF et al. Distribution of drugs following controlled delivery to the brain interstitium. J Neurooncol 1995; 26: 91-102.
10. Young RC. Walker MD, Canellos GP. Initial clinical trials with merhyl-CCNU 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-I-nitrosourea (MeCCNU). Cancer 1973; 31: 1164-9.
11. Fewer D.Wilson CB. Boldrey EB. Phase II study of CCNU in the treatment of brain tumors. Cancer Chem Rep 1972; 56: 421-7.
12. Hoogstraten B, Gottlieb JA, Caoili A. CCNU in the treatment of cancer: A phase II study. Cancer 1973; 32: 38-43.
13. Fine HA, Dear KBG, Loeffler JS. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71 (8): 2585-97.
14. Smart CR, Ottomoan RE, Rochlin DB. Clinical experience with vincristine in tumors of the central nervous system and other malignant diseases. Cancer Chem Rep 1968; 52: 733-41.
15. Rodier JM, Bexon A, Armand JP. Chemotherapy of Malignant Astrocytoma in Adults. 21st ESMO Congress. Vienna. Austria: Educational Book 1996; 193-202.
16. Forsyth PA, Cairncross JG. Chemotherapy for malignant gliomas. In Cerebral Gliomas. Baillière's Clin Neurol 1996; 5 (2): 371-93.
17. Rodriguez LA, Prados M, Silver P. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 1989; 64: 2420-3.
18. Newton HB, Junck L, Bromberg J. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 1990; 40: 1743-6.
19. Cook J, Robinson B, Levi J. Modulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high-grade gliomas. Proc Am Soc Clin Oncol 1997; 16 (Abstr 1375).
20. Heimans JJ, Vermorken JB, Wolbers JG. Paclitaxel concentrations in brain tumor tissue. Ann Oncol 1994; 5: 951-3.
21. Chamberlain MC, Kormanik P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 1995; 13 (8): 2066-71.
22. Prados MD, Schold SC. Spence AM et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 1996: 14(8): 2316-21.
23. Newlands ES, Blackledge GRP, Slack JA et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287-91.
24. Newlands ES. O'Reilly SM, Glaser MG. The Charing Cross Hospital experience with Temozolomide in patients with gliomas. Eur J Cancer 1996; 32A (13): 2236-41.
25. Levin V, Yung A, Prados M. Phase II study of Temodal (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. Proc Am Soc Clin Oncol 1997; 16 (Abstr 1370).
26. Levin VA, Edwards MS, Wright DC. Modified procarbazine. CCNU and vincristine (PCV3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 1980; 64 (2-3): 237-41.
27. Cangir A, Ragub A, Steuber P. Combination chemotherapy with vincristine (NSC 67574). procarbazine (NSC 77213). prednisone (NSC 10023) with or without nitrogen mustard (NSC 762) (MOPP vs OPP) in children with recurrent brain tumors. Med Pediatr Oncol 1984; 12: 1-3.
28. Van Eyse J, Baram T, Cangir A et al. Salvage chemotherapy fro recurrent primary brain tumors in children. J Pediatr 1988; 113. 601-6.
29. Coyle T, Baptista J, Winfield J. Mechlorethamine, vineristine and procarbazine chemotherapy for recurent high-grade glioma in adults: A phase II study. J Clin Oncol 1990; 8 (12): 2014-8.
30. Longee DC, Friedman HS, Albright RE. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 1990; 72: 583-8.
31. Sanson M, Ameri A, Monjour A et al. Treatment of recurrent malignant supralentorial gliomas with ifosfamide, carboplatin. and etoposide: A phase II study. Eur J Cancer 1996; 32A: 2229-35.
32. Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 1992; 10 (5): 766-71.
33. Rujan B, Ross G, Lim CC. Survival in patients with recurrent glioma as a mesure of treatment efficacy: Prognostic factors following nitosourea chemotherapy. Eur J Cancer 1994; 30A: 1809-15.
34. Hildebrand J, Sahmoud T, Mignolet F. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 1994; 44: 1479-83.
35. Levin VA, Silver PBA, Hannigan JMS. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU. procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990: 18: 321-4.
36. Perry JR. Adjuvant chemotherapy for malignant glioma: An analysis of methodology and outcome data from clinical trials. Neurology 1995: 45 (Suppl 4): 386 (Abstr 810S).
37. NijjarTS, Simpson WJ. Gadalla Tet al. Oligodendroglioma.The Princess Margaret Hospital experience (1958 1984). Cancer 1993; 71 (12): 4002-6.
38. Von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia 1995; 15: 328-38.
39. Cairncross G, Macdonald D, Ludwin S. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12 (10): 2013-21.
40. Cairncross G, Swinnen L, Stiff P. High-dose thiotepa with hematopoietic reconstitution (deferring radiation) for newly diagnosed aggressive oligodendroglioma. Proc Am Soc Clin Oncol 1997; 16 (Abstr 1386).
41. Kyritsis AP, Yung WKA, Bruner J et al. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993; 32:365-71.
42. Walter KA, Tamargo RJ, Olivi A. Intratumoral chemotherapy. Neurosurgery 1995; 37(6): 1129-45.
43. Brem H, Mahaley Ms, Vick NA. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991; 74: 441-6.
44. Brem H, Piantadosi S, Burger PC. Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by bio-degradable polymers of chemotherapy for recurrent gliomas. Lancet 1995; 345: 1008-12.
45. Shapiro WR, Green SB, Burger PC. A randomized comparison of intra-arterial rersus intravenous BCNU. with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant ghioma. J Neurosurg 1992; 76: 772-81.
46. Madajewiez S, Chowhan N, Ilya A. Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors. Cancer 1991; 67: 2844-9.
47. Iwadate Y, Namba H, Saegusa T. Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors. J Neuroncol 1993; 15: 185-93.
48. Wolff SN, Phillips GL, Herzig GP. High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade glionms of the central nervous system. Cancer Treat Rep 1987; 71 (2): 183-5.
49. Mbidde EK, Selby PJ, Perren TJ. High-dose BCNU chemotherapy with autologous bone marrow tranplantation and fulldose radiotherapy for grade IV astrocytoma. Br J Cancer 1988; 58: 779-82.
50. Johnson DB, Thompson JM, Corwin JA. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. J Clin Oncol 1987; 5 (5): 783-9.
51. Takvorian T, Parker LM, Hochberg FH. Autologous bone-marrow transplantation: host effects of high-dose BCNU. J Clin Oncol 1983; 1 (10): 610-20.
52. Phillips GL, Woltf SN, Fay JW. Intensive 1.3-bis(2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncol 1986; 4 (5): 639-45.
53. Finlay JL, Goldman S, Wong MC. Pilot study of high-dose thiotepa and etoposide with autologous hone marrow rescue in children and young adults with recurrent CNS minors. J Clin Oncol 1996; 14 (9): 2495-2503.
54. Wong ET, Hess KR, Gleason MJ. Time to tumor progression as a measure of efficacy in phase II chemotherapy trials for recurrent malignant gliomas. Proc Am Soc Clin Oncol 1996; 15 (Abstr 277).
55. Barker FG, Chang SM, Prados MD. Response to Carmustine (BCNU), tumor control, and survival in recurrent glioblastoma multiforme (GM). Proc Am Soc Clin Oncol 1996; 15 (Abstr 307).
56. Macdonald DR, Cascino TL, Clifford Schold S. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8 (7): 1277-80.
57. Ekstrand AJ, Longo N, Hamid ML et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994; 9: 2313-20.
58. Nishikawa R, Ji XD, Harmon RC et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91: 7727-31.
59. Bögler O. Huang HJS, Kleihus P et al. The p53 gene and its role in human brain tumors. Glia 1995; 15: 308-27.
60. Haupt Y, Maya R. Kazaz A et al. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
61. Jen J, Harper JW, Bigner SH et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994; 54: 6353-8.
62. Nishikawa R, Furnari FB. Lin H et al. Loss of p16ink4 expressions is frequent in high-grade gliomas. Cancer Res 1995; 55: 1941-5.
63. He J, Allen JR. Collins VP el al. CDK4 amplification is an alternative mechanisms to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994; 54: 5804-7.
64. Henson JW, Schnitker BL. Correa KM et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994; 36: 714-21.
65. He J, Olson JJ, James CD. Lack of p16ink4 or retinoblastoma protein (pRb) or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995; 55: 4833-6.
66. Li J, Yen C, Liaw D el al. PTEN. a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.
67. Van Meir E, Roemer G. Discrens AC et al. Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 allelles to glioblasloma cells. Proc Nail Acad Sci USA 1995; 92: 1008-12.
68. Gomez-Manzano C, Fueyo J, Kyritsis AP et al. Adenovirusmediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996; 56: 694-9.
69. Lowe SW, Ruley HE, Jacks et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
70. Fujiwara T, Grimm EA, Mukhopadhyay T et al. Induction of chemosentivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287-91.
71. Roth JA, Cristiano R. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
72. Roth JA, Nguyen D, Lawrene DD et al. Retroviral-mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2: 985-91.
73. Minchencko A, Bauer T. Salceda S et al. Hypoxic Stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 1994; 71: 374-9.
74. Kim KJ, Li B. Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivti. Nature 1993; 362: 841-4.
75. Millauer B, Shawer LK, Plate KH et al. Glioblastoma growth inhibited in vivo by a dominant-negative FIk-1 mutant. Nature 1994; 367: 576-9.
76. Millauer B, Longhi MP, Plate KH et al. Dominant-negative inhibition of FIk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56 (7): 1615-20.
77. Tanaka T, Manome Y, Wen P et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angio-genesis and tumor growth. Nature Med 1997; 3: 437-42.
78. June CH, Bluestone JA, Nadler LM et al. The B7 and CD28 receptor families, Immunol Today 1994; 15: 321-31.
79. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-6.
80. Dietrich PY, Saas P,Walker PR et al. Immunobiology of gliomas: New perspectives for therapy. Ann N Y Acad Sci 1997; 824: 124-40.
81. Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor-β-dependent but not the trans-forming growth factor-β-independent pathway of tumor cell-mediated immunosuppression. J Immunol 1992; 148: 277-84.
82. Hishii M, Nitta T, Ishida H et al. Human glioma-derived Interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 1995;37: 1160-7.
83. Saas P, Walker PR, Hahne M et al. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-8.
84. Walker PR, Saas P, Dietrich PY. The role of Fas Ligand (CD95L) in immune escape: The tumor cell strikes back. J Immunol 1997; 158: 4521-4.
85. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
86. Owens T, Renno T, Taupin V et al. Inflammatory cytokines in the brain: Does the CNS shape immune responses? Immunol Today 1994; 15: 566-71.
87. Hafler DA, Weiner HL. In vivo labeling of blood T cells: Rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann Neurol 1987; 22: 89-93.
88. Aoki T, Tashiro K, Miyatake S et al. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 1992; 89: 3850-4.
89. Trojan J, JohnsonTR, Rudin SD et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259: 94-7.
90. Resnicoff M, Sell C, Rubini M et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54: 2218-22.
91. Asai A, Miyagi Y, Hashimoto H et al. Modulation of tumor immunogenicity of rat glioma cells by s-myc expression: Eradication of rat gliomas in vivo. Cell Growth Diff 1994; 5: 1153-8.
92. Fakhrai H, Dorigo O, Shawler DL et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Si USA 1996; 93: 2909-14.
93. Sampson JH, Archer GE. Ashley DM et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CDS+ cell mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc Natl Acad Sci USA 1996; 93: 10399-404.
94. Ashley DM, Faiola B. Nair S et al. Bone marrow derived dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186; 1177-82.
95. Yu JS, Wei MX, Chiocca Ea et al. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 1993; 53: 3125-8.
96. Benedetti S, DiMeco F, Polio B et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transductiort of the IL-4 gene. Hum Gene Ther 1997; 8: 1345-53.
97. Culver KW, Ram Z, Wallbridge S et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-2.
98. Wei MX, Tamiya T, Chase M et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994; 5: 969-78.
99. Weller M, Frei K, Groscurth P et al Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994; 94: 954-64.
100. Weller M, Malipiero U, Rensing-Eh1 A et al. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 1995; 55: 2936-44.
101. Bischoff JR, Kirn DH. Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-6.
102. Heise C, Sampson-Johannes A, Williams A et al. ONYX-015, an EIB gene-attenuated adenovirus. causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 1997; 3: 639-45.
103. Bailar JC, Gornik HL, Cancer undefeated. N Engl J Med 1997; 336: 1569-74.
104. Van Meir EG, Polverini PJ, Chazin VR el al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblasloma cells. Nature Genet 1994; 8: 171-6.
105. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 1996; 2: 1096-103.
106. Voest EE, Kenyon BM. O'Reilly MS et al. Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995; 87: 581-6.